S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:MNKD

MannKind Stock Forecast, Price & News

$3.67
+0.29 (+8.58 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.14
Now: $3.67
$3.68
50-Day Range
$3.14
MA: $4.52
$6.14
52-Week Range
$0.80
Now: $3.67
$6.25
Volume8.84 million shs
Average Volume6.52 million shs
Market Capitalization$907.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
MannKind logo

Headlines

What Does MannKind's Debt Look Like? - Benzinga
February 28, 2021 |  benzinga.com
What Does MannKind's Debt Look Like?
February 26, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000
Employees232
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.04 million
Book Value($0.92) per share

Profitability

Net Income$-51,900,000.00

Miscellaneous

Market Cap$907.07 million
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

589th out of 1,972 stocks

Pharmaceutical Preparations Industry

271st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$3.67
+0.29 (+8.58 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MannKind (NASDAQ:MNKD) Frequently Asked Questions

Is MannKind a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind
or view top-rated stocks.

What stocks does MarketBeat like better than MannKind?

Wall Street analysts have given MannKind a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MannKind wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for MannKind
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings results on Wednesday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. The biopharmaceutical company had revenue of $15.35 million for the quarter, compared to analysts' expectations of $15.74 million.
View MannKind's earnings history
.

How has MannKind's stock been impacted by Coronavirus?

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 233.6% and is now trading at $3.67.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MNKD?

5 analysts have issued 1 year price targets for MannKind's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's share price to reach $6.63 in the next year. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for MannKind
or view top-rated stocks among Wall Street analysts.

Who are MannKind's key executives?

MannKind's management team includes the following people:
  • Dr. Michael E. Castagna, CEO & Director (Age 44, Pay $844.2k)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 58, Pay $630.4k)
  • Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 54, Pay $675.97k)
  • Mr. James Patrick McCauley Jr., J.D., M.B.A., Chief Commercial Officer (Age 55, Pay $614.06k)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 57)
  • Ms. Rosabel Realica Alinaya, VP of Investor Relations & Treasury (Age 60)
  • Dr. Stuart A. Tross, Chief People & Workplace Officer (Age 54)
  • Mr. John F. Bedard, Sr. VP of Worldwide Regulatory Affairs (Age 71)
  • Mr. Alejandro Galindo M.B.A., M.S., Chief Commercial Officer

Who are some of MannKind's key competitors?

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.73%), Avoro Capital Advisors LLC (1.50%), Northern Trust Corp (1.09%), Charles Schwab Investment Management Inc. (0.64%), Nuveen Asset Management LLC (0.55%) and Morgan Stanley (0.51%). Company insiders that own MannKind stock include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind
.

Which major investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Beirne Wealth Consulting Services LLC, GSA Capital Partners LLP, Sowell Financial Services LLC, Wells Fargo & Company MN, Northern Trust Corp, and Dupont Capital Management Corp.
View insider buying and selling activity for MannKind
or view top insider-selling stocks.

Which major investors are buying MannKind stock?

MNKD stock was purchased by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, Nuveen Asset Management LLC, BlackRock Inc., Credit Suisse AG, ClariVest Asset Management LLC, 180 Wealth Advisors LLC, BBR Partners LLC, and Squarepoint Ops LLC. Company insiders that have bought MannKind stock in the last two years include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind
or or view top insider-buying stocks.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $3.67.

How much money does MannKind make?

MannKind has a market capitalization of $907.07 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does MannKind have?

MannKind employs 232 workers across the globe.

What is MannKind's official website?

The official website for MannKind is www.mannkindcorp.com.

Where are MannKind's headquarters?

MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.